Notably, all four mentioned SGLT2 inhibitors have demonstrated potential in decreasing hospitalization for heart failure in diabetic patients, which has motivated further research into SGLT2 inhibitors in heart failure patients. The gene discussed is SLC5A2; the disease is heart failure.